• MEDI2452 is a specific antidote of the platelet P2Y 12 receptor antagonist ticagrelor.
Summary. Background: Ticagrelor, a P2Y 12 antagonist, is approved for the prevention of thromboembolic events. However, antiplatelet therapies carry a risk of bleeding. Objective: To explore the hemostatic effects of MEDI2452, an antidote for ticagrelor. Methods: Pigs, pretreated with aspirin, were given an intravenous infusion of ticagrelor or vehicle. At the end of the infusion, a piece of a liver lobe was cut off and a bolus of MEDI2452 or vehicle was administered intravenously. Blood was collected to monitor blood loss, mean arterial blood pressure (MAP) was recorded and survival time was observed over 4 h. Blood samples for drug plasma exposures and platelet aggregation were collected. Results: MEDI2452 eliminated the free concentrations of ticagrelor and its active metabolite AR-C124910XX within 5 min. ADP-induced platelet aggregation was close to normal at 60 min, which was not significantly different from aspirin alone. MEDI2452 numerically reduced ticagrelor-mediated effects: bodyweight-adjusted blood loss in the 15-to 90-min interval, 12 (confidence interval [CI] 95% 7-28] vs. 17 (CI 95% 5-31) (ticagrelor and aspirin) vs. 5 (CI 95% 3-9) mL kg À1 (aspirin alone), survival 70% (CI 95% 47-100) vs. 45% (CI 95% 21-92) (ticagrelor and aspirin) vs. 100% (CI 95% 100-100) (aspirin alone), and median survival time, 240 (CI 95% 180-240) vs. 169 (CI 95% 64-240) (ticagrelor and aspirin) vs. 240 (CI 95% 240-240) min (aspirin alone). Finally, MEDI2452 significantly attenuated the decline in MAP, 0.08 (CI 95% 0.07-0.09) vs. 0.141 (CI 95% 0.135-0.148) (ticagrelor and aspirin) vs. 0.04 (CI 95% 0.03-0.05) mmHg per min (aspirin alone) and maintained MAP at a significantly higher level, 73 (CI 95% 51-95) vs. 48 (CI 95% 25-70) (ticagrelor and aspirin) vs. 115 (CI 95% 94
Introduction
Ticagrelor is an orally available, direct-acting, selective and reversibly binding P2Y 12 receptor antagonist [1] . The ticagrelor active metabolite AR-C124910XX (30-40% plasma exposure relative to the parent in humans) [2] , has a potency similar to that of ticagrelor vs. P2Y 12 [3] . In addition to P2Y 12 , ticagrelor also inhibits the equilibrative nucleoside transporter-1, thereby providing an enhanced adenosine response [4, 5] . Supported by clinical evidence from the PLATO trial [6] , ticagrelor 90 mg twice daily in combination with low-dose aspirin is approved to reduce major cardiovascular (CV) events in patients with acute coronary syndrome (ACS). Additionally, supported by clinical evidence from the PEGASUS trial [7] , ticagrelor 60 mg twice daily in combination with low-dose aspirin is approved to reduce major CV events in patients with prior myocardial infarction.
Therapy with aspirin (acetylsalicylic acid [ASA]) plus an oral antiplatelet agent such as clopidogrel, prasugrel or ticagrelor is known as dual antiplatelet therapy (DAPT). Although DAPT is strongly recommended in the early management of patients experiencing an ACS event, it also increases the risk of bleeding [8] . Patients with ACS may require urgent or emergent coronary artery bypass graft (CABG) surgery. In such patients, DAPT is associated with a 2-fold increase in the risk of blood transfusion, a 5-fold increase in the risk of reoperation, and a 50% increased risk of wound infection [9, 10] . Consequently, guidelines and guidance statements recommend that the P2Y 12 receptor antagonist be stopped at least 5 days prior to the procedure, a recommendation that is not possible to follow in patients who require urgent surgery.
In the PLATO study, ticagrelor plus ASA reduced the rate of major CV events in patients with ACS significantly more than clopidogrel plus ASA [6] , but with no greater risk of major bleeding events. However, this study also demonstrated that the risk of bleeding in ACS patients treated with DAPT is clinically important. In patients randomized to ticagrelor plus ASA, 11.6% experienced major bleeding, including fatal or life-threatening bleeding [11] . In PLATO, patients who required CABG within 1 day of their most recent ticagrelor dose represented less than 1% of ACS patients treated with ticagrelor (84/9235), but 55/84 (65.5%) experienced CABG-related fatal or life-threatening perioperative bleeding [12] .
There are no approved drugs or biological agents capable of reversing the P2Y 12 inhibition produced by ticagrelor or other P2Y 12 inhibitors. Thus if a major bleeding event occurs in a patient on DAPT, treatment options are limited. Although platelet transfusion restores platelet function in patients on ASA [13] , it does not reverse the antiplatelet effect of ticagrelor in healthy volunteers [14] and is unlikely to be of clinical benefit in patients with bleeding [15] [16] [17] . Platelet transfusion in patients suffering an acute hemorrhagic stroke, mainly on aspirin monotherapy, has even been found to be harmful [18] . The lack of an effective therapy to mitigate ticagrelorinduced platelet inhibition in patients who have life-threatening bleeding or require urgent surgery or intervention therefore represents a significant unmet need.
MEDI2452 is a neutralizing fragment antigen-binding (Fab) that has been shown to bind with high affinity (20 pM) and selectivity to ticagrelor and AR-C124910XX [19] . MEDI2452 has previously been shown to concentration-dependently neutralize the free fraction of ticagrelor and reverse its antiplatelet activity both in vitro in human platelet-rich plasma and in vivo in mice, and to normalize ticagrelor-dependent bleeding in a mouse model of acute surgery [19] . In the present study, we evaluated the ability of MEDI2452 to restore hemostasis in pigs treated with ticagrelor to a supra-therapeutic plasma concentration, on a background of ASA, when dosed after the induction of acute major bleeding.
Methods

Anesthesia and maintenance of homeostasis
Swedish landrace pigs (Persbo G ard, Ransta, Sweden) were pre-medicated with intramuscular dormicum (2 mg kg À1 , Roche AB, Stockholm, Sweden) and ketaminol (10 mg kg
À1
, Intervet International BV, Boxmeer, the Netherlands). An intravenous (IV) bolus dose of pentobarbital sodium (10-15 mg kg
, Apoteksbolaget, Ume a, Sweden) was given, the pigs were intubated and the anesthesia was maintained with a subsequent intravenous (i.v.) infusion of pentobarbital (10) (11) (12) (13) (14) (15) or vehicle (25 mM histidine, 290 mM sucrose, 0.05% (w/v) polysorbate 80, pH 6.0) was administrated for 5 min, starting immediately after liver injury (Fig. 1) . Upon completion of the MEDI2452 dosing the Ringer infusion was increased from 10 to 25 mL kg À1 *h. Blood was collected from the abdominal cavity by a suction device (Bugge cardiac suction tube, Instrumenta AB, Partille, Sweden) at specified time intervals to monitor blood loss. Death was defined as a MAP below 20 mmHg. Total blood loss (mL), as well as survival time (min), was recorded. If animals were still alive at 240 min, they were terminated by a lethal i.v. dose of pentobarbital sodium. Arterial blood was collected at baseline (post-ASA but pre-ticagrelor), after the end of the ticagrelor or vehicle infusion, and at 5, 15, 30, 60, 90, 120, 150, 180, 210 and 240 min after MEDI2452 or vehicle administration. Urine samples were collected after completed ticagrelor infusion and once every hour after MEDI2452 or vehicle administration in a subset of animals. Three groups of pigs were given ASA alone (n = 8), ASA + ticagrelor (n = 9) or ASA + ticagrelor + MEDI2452 (n = 10).
Dosing rationale
The ASA dose was selected to induce strong inhibition of platelet cyclooxygenase 1 (COX1) and thereby arachidonic acid (AA)-induced platelet aggregation. To induce significant ticagrelor-dependent bleeding in the model, the ticagrelor dose was selected to yield a supra-therapeutic plasma concentration, and to achieve high inhibition of adenosine diphosphate (ADP)-induced platelet aggregation throughout the duration of the experiment. The MEDI2452 dose, 600 mg kg
À1
, was selected as a high, investigational dose where the exposure would exceed the exposure of ticagrelor and induce rapid elimination of the free fraction of ticagrelor and AR-C124910XX as predicted by a pharmacokinetic interaction model translated from the published mouse ticagrelor-MEDI2452 model [20] (Data S1).
Platelet aggregation
Immediately after the blood sampling, whole blood was added to the Multiplate Ò impedance aggregometer (Roche Diagnostics GmbH, Mannheim, Germany) and stimulated with ADP (ADPtest, Roche Diagnostics) or AA (ASPItest, Roche Diagnostics) (final assay concentrations 6.5 and 484 lM, respectively) according to the manufacturer's instructions. The platelet aggregation response was recorded for 6 min and data were expressed as the mean area under the curve (AUC) of aggregation unit (AU) recorded over time (AU*min).
Pharmacokinetic analysis
Concentrations of total ticagrelor and AR-C124910XX in plasma and urine The plasma samples were prepared by protein precipitation with internal standard in acetonitrile, followed by a dilution step of the supernatant. The concentrations of total ticagrelor and AR-C124910XX in plasma were then determined with a liquid chromatographic-mass spectrometric (LC-MS/MS) method. The lower limit of quantification (LLOQ) was 0.005 lM. The urine samples were prepared by dilution with internal standard in acetonitrile, followed by a second dilution step with 50% acetonitrile in H 2 O. The concentrations of total ticagrelor and AR-C124910XX in urine were then determined with an LC-MS/MS method; LLOQ was 0.010 lM.
Concentrations of free ticagrelor and AR-C124910XX in plasma Plasma samples were dialyzed on a 96-well equilibrium dialysis plate with membrane molecular weight cut-off of 5000 Daltons (Dispo Equilibrium dialyzer plate, Harvard Apparatus, Holliston, MA, USA) against a pH 7.0 phosphate buffer. The plate was rotated at 37°C for 24 h. Dialysate from the buffer side of the dialysis plate was transferred to a LoBind PCR clean Eppendorf plate containing internal standard in acetonitrile. The samples were mixed and injected on to the LC-MS/MS (Acquity Ultra Performance LC coupled to a Xevo TQ-S Mass Spectrometer, Waters Corp., Milford, MA, USA). LLOQ of the free concentrations of ticagrelor and AR-C124910XX in the dialysate was 0.035 nM.
Concentrations of total MEDI2452 in plasma and urine The Gyrolab
™ nanolitre scale immunoassay assay platform, as previously described [21] , was used to develop an assay for total MEDI2452 in plasma and urine. Biotinylated goat antibody directed against human IgG Fab fragment was utilized as the capture reagent and Alexa Fluor 647-labelled mouse antibody directed against human IgG Fab fragment as the detection reagent. Concentrations were expressed as lM, calculated based on MEDI2452 molecular weight, 47.4 kDa. Plasma and urine assays had LLOQs of 21 and 3 lM, respectively.
Data analysis
Presentation of data Results are presented as descriptive statistics with mean values AE standard error of the mean (SEM) or median, minimum and maximum values, apart from MAP data, where confidence intervals are given. As a consequence of animals dying during the experiments, not all specified samples could be collected in the two ticagrelor groups, whereas all samples could be collected in the ASA alone group, in which all animals survived the full duration of the experiment. The ADP-induced platelet aggregation, % of baseline, was calculated as: % of baseline = (Aggregation t x /Aggregation baseline )*100, where t x represents the different blood sampling timepoints. Death was defined as MAP below 20 mmHg. Hence, this was the fixed value at all time-points postdeath. Maximum survival time was set to 240 min.
Statistical analyses
Statistical analyses were performed using R version 3.2.3. Platelet aggregation differences between groups were assessed through one-sided t-tests based on the pooled estimate of standard deviation, and the corresponding P-values were corrected for multiple testing with the Benjamini-Hochberg method. The Kaplan-Maier estimates for the survival and the survival time medians were tested for significant differences using the Cochran-MantelHaenszel test. MAP was modelled as a function of time using linear mixed-effects regression. The MAP level over the more stable final 2 h in each group, as well as the rate of MAP decrease over time, was tested by the t-tests for the corresponding parameter estimates in the model. Blood-loss data were grouped into two groups according to the timepoints when behavior changes were observed: 15-90 min and total blood loss. Differences were assessed by twoway analysis of variance and all pairwise comparisons were corrected for multiple testing by the Tukey's honest significant difference method. For all tests, a P-value < 0.05 was considered statistically significant.
Results
Pharmacokinetics
At the end of the ticagrelor infusion in the pigs receiving ticagrelor in the absence of MEDI2452, the plasma concentrations of ticagrelor and AR-C124910XX were
0.8 AE 0.09 nM, respectively. The MEDI2452 dose resulted in a total initial MEDI2452 plasma concentration of 170 lM, with a half-life of approximately 1.5 h (Fig. 2) . At 5 min after MEDI2452 dosing and at all subsequent time-points, the plasma concentrations of free ticagrelor and AR-C124910XX were below the LLOQ (0.035 nM) (Fig. 2) . In parallel, MEDI2452 induced a major increase in the plasma concentrations of total ticagrelor and AR-C124910XX (Fig. 2) . The reason for this increase in total concentrations is that MEDI2452 acts like a ticagrelor buffer in the plasma compartment and redistributes ticagrelor and AR-C124910XX from non-plasma (tissue) compartments to the plasma compartment [20] . In the absence of MEDI2452, the concentrations of total ticagrelor and AR-C124910XX in the urine were just above LLOQ (0.010 lM), whereas the addition of MEDI2452 resulted in a marked increase in mean concentrations of total ticagrelor and AR-C124910XX in the urine (Fig. 3) . The published ticagrelor-MEDI2452 mathematical interaction model developed in the mouse [20] , and here translated to the pig, predicted the MEDI2452 pharmacokinetics reasonably well, including the time courses of total and free plasma concentrations of ticagrelor and AR-C124910XX (Data S1).
Platelet aggregation
Ticagrelor inhibited ADP-induced platelet aggregation by 92 AE 2% (8% remaining aggregation relative to baseline) at the end of the ticagrelor infusion, with a gradual recovery to 83 AE 3% inhibition (17% remaining aggregation relative to baseline) at the end of the experiment. MEDI2452 reversed ticagrelor-mediated inhibition of ADP-induced platelet aggregation back to a level of aggregation of 58 AE 9% relative to baseline by 5 min after the MEDI2452 dose (Fig. 4) . There was a slight delay between MEDI2452 plasma exposure and the pharmacodynamic effect, as maximal MEDI2452 exposure occurred at 5 min and ADP-induced aggregation was close to normal at 60 min and all time-points after 60 min, apart from 90 min, when it was not significantly different from the ASA group. This is in line with previously reported mouse data [19, 20] . The relative inhibition induced by ASA alone could not be calculated, as no sample was collected before the ASA dosing. In the ASA group, the AA-induced platelet aggregation was lowest at 15 min, 28 AE 17 AU*min, followed by a gradual increase over time. Ticagrelor treatment enhanced the inhibition of AA-induced platelet aggregation with no apparent effect of MEDI2452 (data not shown).
Survival, blood loss and mean arterial blood pressure
Ticagrelor reduced survival (4/9 vs. 8/8, P < 0.05), reduced survival time (169 vs. 240 [240-240] min, P < 0.05) and increased bodyweight-adjusted total blood loss (37 vs. 16 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 
mL kg
À1
, P < 0.05) compared with ASA alone (Fig. 5) . The ticagrelor-dependent increase in blood loss was present between À5 min and 90 min after vehicle administration, and 36% of the blood loss in ASA + ticagrelor-treated pigs occurred during the first 20 min (Fig. 6) . Thus, the assay window for ticagrelor-enhanced bleeding was between À5 and 90 min. The MAP declined steeply after the liver injury, an effect further augmented by ASA + ticagrelor compared with ASA alone (Fig. 7) . Compared with ASA + ticagrelor, MEDI2452 treatment improved survival and reduced blood loss but the effects did not reach statistical significance: survival (7/10 vs. 4/9, P > 0. 05 , P < 0.05). Considering the assay window for ticagrelor-enhanced bleeding, and the onset time for the effect of MEDI2452, the main opportunity for MEDI2452 to show a beneficial effect was in the 15-90-min interval after the MEDI2452 administration. In this interval, there was a numerical, but statistically non-significant, reduction in bodyweight-adjusted blood loss (12 (Fig. 7) . However, the MAP decrease was still higher and the mean MAP level was still lower in the ASA + ticagrelor + MEDI2452 group compared with the ASA alone group 
Discussion
The aim of the study was to explore to what extent MEDI2452 can restore hemostasis when administered during ongoing major bleeding. This was investigated in a model of acute bleeding in the presence of DAPT with aspirin and ticagrelor. For this purpose, we needed a model that (i) displayed a ticagrelor-dependent enhancement of bleeding so that an effect of MEDI2452 could be evaluated, and (ii) resembled clinical bleeding on DAPT. A large animal species, pig, was selected as having a sufficient blood volume to enable an extended bleeding period to best mimic the clinical situation. An extended bleeding period was also needed to allow MEDI2452 to induce its pharmacological effect (onset about 30 min after dosing, as seen in mice) [19] and still have time remaining to impact hemostasis. All pigs were pre-treated with aspirin to mimic the clinical situation in which all patients receive DAPT. As DAPT is known to enhance bleeding compared with monotherapy, this should also enable a larger ticagrelorenhanced bleeding window. At the end of the ticagrelor infusion, the plasma concentrations of ticagrelor and AR-C124910XX were 3.5 and 0.2 lM, respectively. This is about two times higher than the expected clinical exposure in patients, as the mean maximal plasma concentrations of ticagrelor and AR-C124910XX following 4 weeks of ticagrelor treatment (90 mg b.i.d.) have been documented to be 1.5 and 0.5 lM (770 and 257 ng mL À1 [8] ), respectively.
The pigs were given this high-dose ticagrelor to yield a supra-therapeutic plasma concentration, which enables a sufficient and more consistent ticagrelor-enhanced bleeding window. A liver injury was selected, as the liver has extensive microcirculation, mimicking the diffuse bleeding that clinicians refer to when discussing the bleeding occurring in patients on DAPT undergoing open-heart surgery.
In the pigs, the ticagrelor dose induced strong inhibition of ADP-induced platelet aggregation, similar to the maximal effect seen in patients, and significantly reduced survival and survival time and increased bodyweightadjusted total blood loss compared with aspirin alone. The MAP declined steeply after the liver injury, an effect further augmented by ticagrelor compared with aspirin alone. The mechanism of action of MEDI2452 is to bind up all free ticagrelor and AR-C124910XX and thereby prevent their binding to and inhibition of the platelet P2Y 12 receptor. The protein un-bound fraction, the only fraction that can inhibit P2Y 12 , of ticagrelor and AR-C124910XX is very low (≤ 0.02%) [22] . However, as MEDI2452 binds up free ticagrelor and AR-C124910XX, more free ticagrelor and AR-C124910XX will be made available from the protein-bound compartment as the equilibrium will adjust. Thus, for MEDI2452 to induce a complete reversal of ticagrelor-mediated inhibition of platelet function, all ticagrelor and AR-C124910XX needs to be bound up by MEDI2452. In the pigs, MEDI2452 induced a rapid (within 5 min) and sustained elimination of the free fraction of both ticagrelor and AR-C124910XX, as levels were below the detection limit (0.035 nM) from 5 min and throughout the experiment. In parallel with the elimination of free concentrations, the total plasma concentrations increased substantially, which can be explained by the recruitment of compound from tissue compartments to the plasma compartment. This is completely in line with the mathematical ticagrelor-MED2452 interaction model that has recently been published [20] .
Normally, in the absence of MEDI2452, ticagrelor is excreted in the feces, with renal excretion playing only a minor role. The primary route of excretion for AR-C124910XX is most likely biliary secretion [23] . The interaction model predicts that in the presence of MEDI2452, ticagrelor changes its route of excretion to renal in complex with MEDI2452 [20] . The present data validate this prediction, as total levels of intact ticagrelor and AR-C124910XX in the urine were just above the detection limit in the absence of MEDI2452, whereas high urine concentrations were present in the presence of MEDI2452. Furthermore, the interaction model contains a special observation model that predicts a difference between the observed free concentrations and actual free concentrations of ticagrelor and AR-C124910XX. This difference is a result of post-sampling equilibration ex vivo (Data S1). As suggested in Figure S3 , this effect may lead to a transient (20 min) underestimation of actual free concentrations of ticagrelor and AR-C124910XX by roughly one order of magnitude. This effect may contribute to the delayed impact on platelet aggregation, but the extent of such a contribution was not quantified.
Clearly MEDI2452 carried out its task, to eliminate free ticagrelor and AR-C124910XX, and thereby restored platelet function. Even if this did not translate into a significant effect on hemostatic parameters, all effects pointed in the right direction, with numerical improvements in blood loss, survival and survival time. Importantly, the MAP decline and final level was significantly attenuated and elevated, respectively. Thus, the efficacy data in this pig model do indicate that MEDI2452 would be clinically effective if acute bleeding occurred in a patient treated with ticagrelor and potentially even more so in the clinical situation in which other supportive means would be used in combination with MEDI2452. There are some limitations to this study. It is a tough challenge to establish a clinically relevant animal model of acute ongoing bleeding, as the clinical situation and treatment are not standardized and thus hard to mimic. To enable a manageable and ethical sample size, animal models need to be standardized. The severe model used led to high initial blood loss and significant mortality, which probably explains why the effects on blood-loss and survival of MED12452 did not reach significance. as the antidote needs time to induce its pharmacological effect.
In conclusion, in pigs dosed to a supra-therapeutic level of ticagrelor exposure on a background of aspirin, MEDI2452, administered after liver injury, eliminated free ticagrelor and AR-C124910XX within 5 min. This translated into a gradual normalization of ADP-induced platelet aggregation, numerical, but not statistically significant, improvements in blood loss and survival, and statistically significant improvements in MAP. The pharmacological profile of MEDI2452 warrants further preclinical and clinical investigation. If successful, this Fab has the potential to be a valuable agent for ticagrelor patients with regard to both treating the rare emergency of life-threatening bleeding and the need for urgent surgery.
